Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage?

M. R. Romano, S. K. Gibran, J. Marticorena, D. Wong, H. Heimann

Research output: Contribution to journalArticle

Abstract

Aims: To evaluate the recurrence rate of vitreous haemorrhage (VH) in patients treated with one intravitreal bevacizumab (IVB) injection (2.5 mg/0.1 ml) before planned pars plana vitrectomy for treatment of diabetic non-clearing VH. Methods: Prospective pilot study of 32 eyes of 31 consecutive diabetic patients who underwent IVB injection within 1 week before surgery for persistent VH in the presence of active proliferative diabetic retinopathy. Three masked retinal specialists graded the amount of VH from grade 0 to grade 3 with slit-lamp biomicroscopy. Main outcome measures were the rate of recurrence of the VH, improvement in visual acuity, incidence of cataract formation, and postoperative complications through a follow-up of 6 months. Results: The percentage of severe recurrent VH with no fundus details (grade 3) was 3% at 1 week follow-up and 3, 6, and 6% respectively at 1-, 3-, and 6-month follow-up. The mean best-corrected visual acuity (BCVA) improved from 1.6 (1/60) to 0.40 (6/15) logMAR (P=0.02) in 29 out of 32 eyes (91%). In all, 12 out of 22 (54%) phakic eyes developed cataract during the follow-up period, and 10 (31%) of them underwent cataract surgery. Conclusions: Our study suggests that IVB injection few days before planned surgery seems to be efficacious and safe as an adjuvant treatment to prevent rebleeding in eyes undergoing pars plana vitrectomy for treatment of diabetic vitreous haemorrhage. IVB facilitates the surgery and reduces the need for extensive delamination and segmentation, decreasing the possibility of significant early active postoperative VH.

Original languageEnglish
Pages (from-to)1698-1701
Number of pages4
JournalEye (London, England)
Volume23
Issue number8
DOIs
Publication statusPublished - Aug 2009

Fingerprint

Vitreous Hemorrhage
Injections
Intravitreal Injections
Cataract
Temazepam
Vitrectomy
Visual Acuity
Recurrence
Postoperative Hemorrhage
Bevacizumab
Diabetic Retinopathy
Therapeutics
Outcome Assessment (Health Care)
Prospective Studies
Incidence

Keywords

  • Preoperative bevacizumab injection
  • Proliferative diabetic retinopathy
  • Vitreous haemorrhage

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage? / Romano, M. R.; Gibran, S. K.; Marticorena, J.; Wong, D.; Heimann, H.

In: Eye (London, England), Vol. 23, No. 8, 08.2009, p. 1698-1701.

Research output: Contribution to journalArticle

Romano, M. R. ; Gibran, S. K. ; Marticorena, J. ; Wong, D. ; Heimann, H. / Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage?. In: Eye (London, England). 2009 ; Vol. 23, No. 8. pp. 1698-1701.
@article{ed335329481e4f938d7db8cb3bb63c4d,
title = "Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage?",
abstract = "Aims: To evaluate the recurrence rate of vitreous haemorrhage (VH) in patients treated with one intravitreal bevacizumab (IVB) injection (2.5 mg/0.1 ml) before planned pars plana vitrectomy for treatment of diabetic non-clearing VH. Methods: Prospective pilot study of 32 eyes of 31 consecutive diabetic patients who underwent IVB injection within 1 week before surgery for persistent VH in the presence of active proliferative diabetic retinopathy. Three masked retinal specialists graded the amount of VH from grade 0 to grade 3 with slit-lamp biomicroscopy. Main outcome measures were the rate of recurrence of the VH, improvement in visual acuity, incidence of cataract formation, and postoperative complications through a follow-up of 6 months. Results: The percentage of severe recurrent VH with no fundus details (grade 3) was 3{\%} at 1 week follow-up and 3, 6, and 6{\%} respectively at 1-, 3-, and 6-month follow-up. The mean best-corrected visual acuity (BCVA) improved from 1.6 (1/60) to 0.40 (6/15) logMAR (P=0.02) in 29 out of 32 eyes (91{\%}). In all, 12 out of 22 (54{\%}) phakic eyes developed cataract during the follow-up period, and 10 (31{\%}) of them underwent cataract surgery. Conclusions: Our study suggests that IVB injection few days before planned surgery seems to be efficacious and safe as an adjuvant treatment to prevent rebleeding in eyes undergoing pars plana vitrectomy for treatment of diabetic vitreous haemorrhage. IVB facilitates the surgery and reduces the need for extensive delamination and segmentation, decreasing the possibility of significant early active postoperative VH.",
keywords = "Preoperative bevacizumab injection, Proliferative diabetic retinopathy, Vitreous haemorrhage",
author = "Romano, {M. R.} and Gibran, {S. K.} and J. Marticorena and D. Wong and H. Heimann",
year = "2009",
month = "8",
doi = "10.1038/eye.2008.354",
language = "English",
volume = "23",
pages = "1698--1701",
journal = "Eye",
issn = "0950-222X",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage?

AU - Romano, M. R.

AU - Gibran, S. K.

AU - Marticorena, J.

AU - Wong, D.

AU - Heimann, H.

PY - 2009/8

Y1 - 2009/8

N2 - Aims: To evaluate the recurrence rate of vitreous haemorrhage (VH) in patients treated with one intravitreal bevacizumab (IVB) injection (2.5 mg/0.1 ml) before planned pars plana vitrectomy for treatment of diabetic non-clearing VH. Methods: Prospective pilot study of 32 eyes of 31 consecutive diabetic patients who underwent IVB injection within 1 week before surgery for persistent VH in the presence of active proliferative diabetic retinopathy. Three masked retinal specialists graded the amount of VH from grade 0 to grade 3 with slit-lamp biomicroscopy. Main outcome measures were the rate of recurrence of the VH, improvement in visual acuity, incidence of cataract formation, and postoperative complications through a follow-up of 6 months. Results: The percentage of severe recurrent VH with no fundus details (grade 3) was 3% at 1 week follow-up and 3, 6, and 6% respectively at 1-, 3-, and 6-month follow-up. The mean best-corrected visual acuity (BCVA) improved from 1.6 (1/60) to 0.40 (6/15) logMAR (P=0.02) in 29 out of 32 eyes (91%). In all, 12 out of 22 (54%) phakic eyes developed cataract during the follow-up period, and 10 (31%) of them underwent cataract surgery. Conclusions: Our study suggests that IVB injection few days before planned surgery seems to be efficacious and safe as an adjuvant treatment to prevent rebleeding in eyes undergoing pars plana vitrectomy for treatment of diabetic vitreous haemorrhage. IVB facilitates the surgery and reduces the need for extensive delamination and segmentation, decreasing the possibility of significant early active postoperative VH.

AB - Aims: To evaluate the recurrence rate of vitreous haemorrhage (VH) in patients treated with one intravitreal bevacizumab (IVB) injection (2.5 mg/0.1 ml) before planned pars plana vitrectomy for treatment of diabetic non-clearing VH. Methods: Prospective pilot study of 32 eyes of 31 consecutive diabetic patients who underwent IVB injection within 1 week before surgery for persistent VH in the presence of active proliferative diabetic retinopathy. Three masked retinal specialists graded the amount of VH from grade 0 to grade 3 with slit-lamp biomicroscopy. Main outcome measures were the rate of recurrence of the VH, improvement in visual acuity, incidence of cataract formation, and postoperative complications through a follow-up of 6 months. Results: The percentage of severe recurrent VH with no fundus details (grade 3) was 3% at 1 week follow-up and 3, 6, and 6% respectively at 1-, 3-, and 6-month follow-up. The mean best-corrected visual acuity (BCVA) improved from 1.6 (1/60) to 0.40 (6/15) logMAR (P=0.02) in 29 out of 32 eyes (91%). In all, 12 out of 22 (54%) phakic eyes developed cataract during the follow-up period, and 10 (31%) of them underwent cataract surgery. Conclusions: Our study suggests that IVB injection few days before planned surgery seems to be efficacious and safe as an adjuvant treatment to prevent rebleeding in eyes undergoing pars plana vitrectomy for treatment of diabetic vitreous haemorrhage. IVB facilitates the surgery and reduces the need for extensive delamination and segmentation, decreasing the possibility of significant early active postoperative VH.

KW - Preoperative bevacizumab injection

KW - Proliferative diabetic retinopathy

KW - Vitreous haemorrhage

UR - http://www.scopus.com/inward/record.url?scp=69049096319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69049096319&partnerID=8YFLogxK

U2 - 10.1038/eye.2008.354

DO - 10.1038/eye.2008.354

M3 - Article

C2 - 19039332

AN - SCOPUS:69049096319

VL - 23

SP - 1698

EP - 1701

JO - Eye

JF - Eye

SN - 0950-222X

IS - 8

ER -